• Target：
• Bcl-10

• Fields：
• >>NF-kappa B signaling pathway;>>C-type lectin receptor signaling pathway;>>T cell receptor signaling pathway;>>B cell receptor signaling pathway;>>Shigellosis;>>Tuberculosis

• Gene Name：
• BCL10

• Protein Name：
• B-cell lymphoma/leukemia 10

• Human Gene Id：
• 8915

• Human Swiss Prot No：
• O95999

• Mouse Gene Id：
• 12042

• Mouse Swiss Prot No：
• Q9Z0H7

• Rat Gene Id：
• 83477

• Rat Swiss Prot No：
• Q9QYN5

• Immunogen：
• The antiserum was produced against synthesized peptide derived from human BCL10. AA range:111-160

• Specificity：
• Bcl-10 Polyclonal Antibody detects endogenous levels of Bcl-10 protein.

• Formulation：
• Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.

• Source：
• Polyclonal, Rabbit,IgG

• Dilution：
• WB 1:500 - 1:2000. IHC 1:100 - 1:300. ELISA: 1:40000.. IF 1:50-200

• Purification：
• The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

• Concentration：
• 1 mg/ml

• Storage Stability：
• -15°C to -25°C/1 year(Do not lower than -25°C)

• Other Name：
• BCL10;CIPER;CLAP;B-cell lymphoma/leukemia 10;B-cell CLL/lymphoma 10;Bcl-10;CARD-containing molecule enhancing NF-kappa-B;CARD-like apoptotic protein;hCLAP;CED-3/ICH-1 prodomain homologous E10-like regulator;CIPER;Cellular homolog

• Observed Band(KD)：
• 36kD

• Background：
• This gene was identified by its translocation in a case of mucosa-associated lymphoid tissue (MALT) lymphoma. The protein encoded by this gene contains a caspase recruitment domain (CARD), and has been shown to induce apoptosis and to activate NF-kappaB. This protein is reported to interact with other CARD domain containing proteins including CARD9, 10, 11 and 14, which are thought to function as upstream regulators in NF-kappaB signaling. This protein is found to form a complex with MALT1, a protein encoded by another gene known to be translocated in MALT lymphoma. MALT1 and this protein are thought to synergize in the activation of NF-kappaB, and the deregulation of either of them may contribute to the same pathogenetic process that leads to the malignancy. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Mar 2016],

• Function：
• disease:A chromosomal aberration involving BCL10 is recurrent in low-grade mucosa-associated lymphoid tissue (MALT lymphoma). Translocation t(1;14)(p22;q32). Although the BCL10/IgH translocation leaves the coding region of BCL10 intact, frequent BCL10 mutations could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.,disease:Defects in BCL10 are involved in various types of cancer.,function:Promotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK. May be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex. Is a substrate for MALT1.,PTM:Phosphorylated. Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2.,similarity:Contains 1 CARD domain.,subcellular location:Appears to have a perinuclear, compact and filamentous pattern of expression. Also

• Subcellular Location：
• Cytoplasm, perinuclear region . Membrane raft . Appears to have a perinuclear, compact and filamentous pattern of expression. Also found in the nucleus of several types of tumor cells. Colocalized with DPP4 in membrane rafts. .

• Expression：
• Ubiquitous.

MALT1 Protease Regulates T-Cell Immunity via the mTOR Pathway in Oral Lichen Planus INFLAMMATION Wang Xiao-Feng IHC,WB Human 1:200,1:1000 oral mucosa tissue Jurkat T cell

• June 19-2018
• WESTERN IMMUNOBLOTTING PROTOCOL

• June 19-2018
• IMMUNOHISTOCHEMISTRY-PARAFFIN PROTOCOL

• June 19-2018
• IMMUNOFLUORESCENCE PROTOCOL

• September 08-2020
• FLOW-CYTOMEYRT-PROTOCOL

• May 20-2022
• Cell-Based ELISA│解您多样本WB检测之困扰

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-ACETYL-PROTEIN

• July 13-2018
• CELL-BASED-ELISA-PROTOCOL-FOR-PHOSPHO-PROTEIN

• July 13-2018
• CELL-BASED-COLORIMETRIC-ELISA-PROTOCOL-FOR-TOTAL-PROTEIN

• July 13-2018
• Antibody-FAQs